NLR

NLR Bio is a biotechnology company focused on developing next-generation small molecule inhibitors of the NLR (nucleotide-binding domain and leucine-rich repeat-containing) family of proteins, with a primary emphasis on the NLRP3 inflammasome. Founded on the pioneering research of Dr. Jenny Ting at the University of North Carolina at Chapel Hill, the company targets chronic inflammation as a central driver of various debilitating diseases. Their therapeutic pipeline aims to address significant unmet needs in neurodegeneration, metabolic disorders, and cardiovascular health by modulating innate immune responses. NLR Bio utilizes a proprietary discovery platform to identify potent and highly selective inhibitors capable of transforming the treatment landscape for inflammation-driven pathologies. The company is venture-backed and operates within the Research Triangle Park biotechnology ecosystem.